

The Point for North America

Monday, 17 March 2025

[Top Call](#) | [Other Morning Call Highlights](#) | [Company](#) | [Industry](#) | [Economics & Strategy](#) | [Fixed Income & FX](#) | [Key Rating and Target Price Changes](#)

Top Call

US Equity Strategy – Shifting Sands V.2


Our broader US equity narrative headed into '25 remains mostly intact. However, there are several twists and turns that need to be considered as the policy and macro backdrop continues to evolve. We continue to view 5,500 as a level that sets up for a good risk reward between our bear and base cases. Shifting sands relate to increased recession concerns but offset by an improved valuation circumstance for the meg cap growth cohort.

[Scott T Chronert](#) | [Drew Pettit](#) | [Patrick Galvin, CFA](#)


Must Read

[Multi-Asset – North America Road Ahead 2025](#)

Industry Group Cluster P/E (TTM)



Mag 7 vs. Rest of Index P/E (NTM)



Cooper Companies Inc (COO.O) – On the Road with COO Management

We had Dan McBride, EVP and COO from CooperCompanies on the road in London, in a timely set of meetings post 1QFY25 results. It is fair to say the FY1Q disappointed ([link](#)), with CVI sales increasing ~6.3% y/y, the lowest growth rate since the 1QFY21 as we exited the pandemic. The culprit was associated with MyDay supply constraints and softer sales in China, both of which are within management's control to remedy (and which are expected to improve throughout the remainder of the year). This said, we are lowering our 2QFY25 revenue to reflect a more gated recovery, without change to our 2QFY25 EPS, or FY revenue or EPS. To us, the contact lens market remains strong and while the last two CVI quarters have fallen below historical growth trends, we do not see a change in market fundamentals, including patient demand. We reiterate our Buy on COO.

[Joanne Wuensch](#)

See Appendix A-1 for Analyst Certification, Important Disclosures and Research Analyst Affiliations.

Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Certain products (not inconsistent with the author's published research) are available only on Citi's portals.


Other Morning Call Highlights

US Oil & Gas Exploration and Production – How Break-Evens Change Post Year-End Updates; Model Updates

Corporate break-evens encapsulate both operational and capital efficiency into a single figure. As a result, the change in break-evens reveals the relative pace of efficiency improvement across the E&Ps, with 4Q updates providing important insights. PR's break-even has improved, down by ~\$2 given longer laterals and continued efficiency improvements. FANG's break-even dropped by ~\$1 to a peer-low \$35 given the improvement and greater gas volumes (less oil CF dependent). EOG's break-even has crept up to ~\$42/bbl (from ~\$39/bbl) as gas production growth guidance is lower than our previous expectations and realizations are forecast to be less robust (oil differentials going down). CTRA's break-even goes up to ~\$39/bbl after its Permian acquisitions as its production profile becomes more oil-levered. DVN's break-even increases slightly by ~\$1 to \$50/bbl as we refine our model.

Scott Gruber

"Oily" E&P break-evens (@ consistent \$2.75/mcf HH)



US Oil & Gas Equipment and Services – What are OFS Stocks Discounting?

A common question recently has been – what are OFS stocks discounting? Determining this is more art than science (especially versus E&Ps, detailed [here](#)). We utilize a blend of 'normal' EV/EBITDA multiples and FCF yields to estimate the magnitude of EBITDA reduction that the larger OFS stocks appear to be discounting. We estimate the stocks are discounting a ~20% drop in EBITDA, led by HAL (~30%) and WFRD (~23%) with SLB and NOV both ~20%. We think this corresponds with a 75-100 U.S. rig count reduction (13-17% drop), a high-single-digit decline in International revenues and healthy decrements. This would broadly correspond with \$58/\$55 Brent/WTI prices. While there's risk of a spending slowdown, we don't think these conditions will sustain into perpetuity and thus the group presents good value. We think SLB, BKR and FTI more easily attract longer term investment while HAL and WFRD likely present higher beta toward industry sentiment.

Scott Gruber


US Exploration & Production and Oil Services – Oil Price to Rig Count to Shale Production In a Single Chart

Continued concerns toward the economy, OPEC's stated intent to unwind production cuts and more recently, potential steps toward a ceasefire in Ukraine have all weighed on Energy equities. One question we've received is – how would

U.S. drilling activity respond to lower prices? In figure 1, we show a rough estimate for how incrementally lower oil prices could impact U.S. oil rig count and shale production. The conclusion is that at ~\$70 WTI, oil production likely grows by ~100kbpd (ex NGLs) but at ~\$65, rig count is likely down ~25 with production flattish. A drop into the upper \$50s likely results in a bigger psychological impact with the rig count potentially falling ~75 and production down >300kbpd. Notably oil-levered E&Ps appear to be discounting ~\$60 WTI with the equities taking a more cautious view than the commodity at present, but closer to the forward curve in Dec. 2026.

[Scott Gruber](#) | [Paul Diamond](#)

How a Drop in Oil Price Could Impact US Oil Rig Count & Production



Trade Desk Inc (TTD.O) - Takeaways from CTV Connect Conference: Incrementally Negative, but Still Buy Rated on Competition and Industry Trends

We attended the CTV Connect conference and offer key takeaways for TTD and broader CTV. We came away from the conference incrementally negative on some key factors for TTD's path to billings recovery and mid-20% revenue growth, most notably that the DSP (and SSP) competitive environment is getting more challenging and that the shift of ad dollars from Linear TV to biddable programmatic CTV has some hurdles to work through, with Linear and direct buying of CTV still a key component of many advertiser/agency plans. We also heard some concerns around the Kokai platform roll out and OpenPath transparency. But we also believe investor sentiment has shifted too negative, that TTD remains a strong competitor in CTV, and that the broader CTV shift will still play in favor of relative strong growth for TTD, even with a more competitive backdrop. We lower our target multiple, but maintain our Buy rating.

[Ygal Arounian](#)

The Trade Desk Estimates Summary

	1Q25E			2025E		2026E	
(\$ in millions, except per share amounts)	Citi Estimates	Consensus Estimates	Guidance Mid-Pt.	Citi Estimates	Consensus Estimates	Citi Estimates	Consensus Estimates
Financial Metrics:							
Revenue	575.9	576.1	575.0	2,878.6	2,884.1	3,425.1	3,462.7
Y/Y growth	17.2%	17.3%	17.0%	17.7%	18.0%	19.0%	20.1%
GAAP Gross Profit	446.0	443.6		2,316.6	2,313.2	2,773.8	2,783.3
Y/Y growth	15.1%	14.4%		17.4%	17.3%	19.7%	20.3%
% Margin	77.4%	77.0%		80.5%	80.2%	81.0%	80.4%
Adj. EBITDA	145.3	149.0	145.0	1,115.9	1,125.1	1,355.5	1,401.1
Y/Y growth	-10.2%	-7.9%	-10.3%	10.4%	11.3%	21.5%	24.5%
% Margin	25.2%	25.9%	25.2%	38.8%	39.0%	39.6%	40.5%
GAAP EPS, diluted	\$0.00	\$0.04		\$0.82	\$0.88	\$1.12	\$1.20
Y/Y growth	-97.4%	-37.1%		5.1%	12.4%	36.3%	36.7%
FCF	174.0	180.7		851.6	776.8	1,012.1	978.8
Y/Y growth	-1.3%	2.5%		34.7%	22.8%	18.8%	26.0%
% Margin	30.2%	31.4%		29.6%	26.9%	29.5%	28.3%
Operating Metrics							
Gross Billings	2,781.9	2,975.3		13,904.6	14,488.4	16,546.5	17,529.2
Y/Y growth	17.8%	26.0%		18.3%	23.3%	19.0%	21.0%
Take Rate	20.7%	19.4%		20.7%	19.9%	20.7%	19.8%


Company

Micron Technology Inc (MU.O) – Earnings Preview – Expect Decent Results But Below Consensus Guide. But Upturn Is Still Intact and Upside is Coming. Reit Buy

Micron will report F2Q25 results on March 20 after market close. We expect the company to post decent results but guide below Consensus driven by worse consumer mix and NAND (26% of F1Q25 sales) underutilization charges. However, mainstream DDR5 spot pricing is inflecting up as pricing is up nearly 8% YTD, the largest increase since 1Q24 and we believe this supports our belief that DRAM pricing should improve beginning in 2Q25. We remain optimistic on Micron given their AI HBM opportunity and bullish on the DRAM recovery given supply/demand dynamics for C25, and our F26 EPS estimate is 39% above Consensus. We reiterate our Buy rating and maintain our price target of \$150 on Micron.

Christopher Danelly

MU NTM P/E



Emerson Electric Co. (EMR.N) – Favorable L-T Trends Intact; Resuming Coverage with a Buy

We're renewed our rating after a period of Rating Suspended on EMR with a Buy rating and a \$132 target price given what we view as a favorable position in markets with still positive underlying long-term fundamentals (despite increased near-term uncertainty) coupled with a strong track record of operational execution that we think should drive outsized financial returns over time. In the near-term, we wouldn't be surprised if sluggishness in EMR's discrete automation end

markets were somewhat more persistent vs. prior expectations, but relative strength in hybrid and process automation end markets remains encouraging. Continued global investment in end markets such as Power and Energy, in which we view EMR as being competitively advantaged, we think should remain tailwinds for the company and, with Aspen Technologies now fully consolidated, we see incrementally more focused execution of EMR's software strategy could as a potential L-T tailwind to growth and profitability.

Andrew Kaplowitz

Bull/Bear: Emerson Electric Co.



Phillips 66 (PSX.N) – Not a Sprint, it's a Marathon; Taking a Closer Look at PSX Financials

PSX is facing an activist ahead of its Annual Meeting scheduled for May. Though it feels the same, the current situation is different from the one faced by MPC in 2019 when “upgrade” in executive management and sale of a large retail footprint were among the suggestions. While we agree to upside in PSX stock, we are unsure about outright sale of businesses is the best way forward. To find a middle path, we take a page from MPC's playbook and showcase that PSX can also create a stable and more transparent corporate structure without pursuing fire sale of assets. If there is a valuation disconnect, a future spin/sale is an option. That's said, improving refining appears to be the real value creation opportunity. Our deep dive into PSX's Opex indicates there is clear room for improvement.

Vikram Bagri

Hypothetical PSX Midstream (\$ in mm)

Midstream	2025	2026	2027	2028	2029	2030
Adjusted EBITDA	3,334	3,413	3,615	3,700	3,787	3,875
Less: Interest Expense	(\$446)	(\$433)	(\$415)	(\$395)	(\$373)	(\$349)
Less: Maintenance Capex	(\$80)	(\$82)	(\$87)	(\$89)	(\$91)	(\$93)
Taxes and Other	\$0	\$0	\$0	\$0	\$0	\$0
Distributable Cash Flow	\$2,808	\$2,899	\$3,114	\$3,216	\$3,322	\$3,432
Growth Capex	\$895	\$893	\$888	\$886	\$884	\$882
Coverage Ratio	1.7x	1.7x	1.7x	1.7x	1.7x	1.7x
Dividend Paid	\$1,652	\$1,705	\$1,831	\$1,892	\$1,954	\$2,019
Dividend/sh	\$1.40	\$1.45	\$1.55	\$1.60	\$1.66	\$1.71
Yield	7.00%	7.23%	7.76%	8.02%	8.28%	8.56%
Net Debt/Adjusted EBITDA	3.0x	2.8x	2.6x	2.4x	2.2x	2.0x
Assumed Debt	\$9,913	\$9,613	\$9,219	\$8,781	\$8,297	\$7,766
Assumed Share Price	\$20	\$20	\$20	\$20	\$20	\$20
Assumed Shares Outstanding	1,180	1,180	1,180	1,180	1,180	1,180
Market Cap	\$23,596	\$23,596	\$23,596	\$23,596	\$23,596	\$23,596
Enterprise Value	\$33,509	\$33,208	\$32,815	\$32,377	\$31,893	\$31,361
Implied EV/EBITDA	10.1x	9.7x	9.1x	8.8x	8.4x	8.1x
PSX Ownership	80%	80%	80%	80%	80%	80%
PSX Ownership Value	\$18,877	\$18,877	\$18,877	\$18,877	\$18,877	\$18,877
PSX Dividend Per Year	\$1,321	\$1,364	\$1,465	\$1,513	\$1,563	\$1,615
Proceeds from IPO (Pre-Tax)	\$4,719					
Proceeds from IPO (Post-Tax)	\$3,889					

Alnylam Pharmaceuticals, Inc. (ALNY.O) - Amvuttra FDA Approval for ATTR-CM Imminent

The FDA is likely to approve Amvuttra (vutrisiran) for its second treatment indication, ATTR-CM (already approved ATTR-PN), later this week on or before March 23, 2025 (FDA action or PDUFA date). On the approval, investors will conduct a detailed examination of the treatment label while also listening for management commentary regarding pricing in addition to offering more detail on its launch strategy. Overall, we expect Amvuttra will be approved with a broad usage label allowing for use in new to therapy patients as well as those on or post-ATTR stabilizer treatment. Next, we expect Amvuttra will be priced at a material premium to the stabilizers; although it will be below current pricing under its ATTR-PN only treatment label. Alnylam is set for a successful launch into this multibillion-dollar indication. The upcoming approval is a key positive catalyst for the stock, that sets the stage for further inflection in the stock.

David Lebowitz, CFA

Rubrik, Inc. (RBRK.N) - F4Q25 Review + Callback Color: This One's Definitely a Keeper

In one of the smoothest, highest-quality CY24 finishes across our coverage, RBRK hit multiple execution marks: accelerating revs growth (~44% YoY PF 1x/non-recurring), subs ARR growth (37% YoY PF transition; Cloud ARR still clocking-in ~70% YoY at ~\$900M scale; 53% NNARR YoY), and blowout OPM/Subs-ARR-CM/FCFM, with much of this momentum carried into the F1Q26/FY26E outlook generally above consensus, particularly on profit-based vectors. In a market backdrop finally "seeing-the-light" on the necessary fusion of modern data protection + cyber-resiliency, and increasingly GenAI data exposure risks, RBRK's pioneering message is delivering the goods, evidenced by accelerating \$100K Subs ARR and meaningful YoY step-up in \$1M ARR customers, both reinforcing RBRK's ongoing profitable-share gain potential in a staid market, even as competitors turn up noise/heat/defensive account control tactics. With Street-high CitiE topline tweaked, margins higher, and a conservative-looking -13% YoY NNARR set-up, the NTM beat-and-raise cadence keeps us constructive; reiterate Buy and \$85PT.

\$ millions, except per share item	Reported	Consensus		Citi Estimates		Guidance			
	Metrics	Metrics	Reported Δ	Metrics	Reported Δ	Metrics			Reported Δ
			\$/bps		\$/bps	Low	Mid	High	\$/bps
4QA FY2025									
Subs ARR	1,092.6	1,059.5	33.1	1,061.0	31.6				
Y/Y %	39.4%	35.1%	422bps	35.3%	403bps				
Cloud ARR	876.0			835.2	40.8				
Y/Y %	66.9%			59.1%	778bps				
Subscription Revs	243.7			220.5	23.2				
Y/Y %	53.6%			39.0%	1,460bps				
Total Revs	258.1	233.1	25.0	233.5	24.6	231.5	232.5	233.5	25.6
Y/Y %	47.5%	33.2%	1,428bps	33.4%	1,404bps	32.3%	32.8%	33.4%	1,463bps
EBIT	(29.0)	(65.5)	36.4	(66.8)	37.7				
% Margin	-11.2%	-28.1%	1,684bps	-28.6%	1,734bps				
ARR Contribution Margin	2%			-2%	424bps	-3.0%	-2.5%	-2.0%	468bps
EPS	(\$0.18)	(\$0.39)	\$0.21	(\$0.38)	\$0.20	(\$0.41)	(\$0.39)	(\$0.37)	\$0.21
CFO	83.6	18.7	64.8	22.1	61.5				
FCFE	75.2	10.9	64.3	14.1	61.1				
% Margin	29.1%	4.7%	2,446bps	6.0%	2,311bps				


Ally Financial Inc (ALLY.N) - Model Update - Market Continues to Discount Strong Underlying Trends; Reit Buy

We are refreshing our ALLY model ahead of 1Q earnings, including updated mgmt. guidance from recent industry conference, which points to solid trends in retail auto losses, and using our vintage curve analysis, we expect '25 auto NCOs of ~212bps (vs guide of 200-225bps). We see NIM expansion through '25 and '26, ending 2026 at ~3.9% as ALLY continues to benefit from fixed rate asset and a remix out of mortgage loans and securities and into higher returning retail auto loans, as well as deposit repricing, where we expect betas will be ~65% particularly given expectations for balance sheet optimization vs growth. With the pending sale of the credit card book, organic growth, and optionality through CRT deals, we see ALLY achieving their 9.5-10% CET1 target (on pro-forma basis) in '26, and anticipate buybacks will resume next year. We continue to see upside to consensus numbers; reiterate Buy.

Keith Horowitz, CFA

The 2023 vintage delinquencies continue to improve, narrowing the spread to our benchmark '21 vintage in 4Q, and with the '24 vintage outperforming the improving '23 vintage, we see a path to ~190bps of NCOs in '26, near the 160-180bps normalized range.

Our med-term estimates are lower on revised NII outlook, though our '27 are improving on strong credit trends.



Ann. Expend.	2000			2001			2002		
	2000	2001	% chg.	2000	2001	% chg.	2000	2001	% chg.
State	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
Federal	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	20,000	20,000	0.0%	20,000	20,000	0.0%	20,000	20,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	30,000	30,000	0.0%	30,000	30,000	0.0%	30,000	30,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	40,000	40,000	0.0%	40,000	40,000	0.0%	40,000	40,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	50,000	50,000	0.0%	50,000	50,000	0.0%	50,000	50,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	60,000	60,000	0.0%	60,000	60,000	0.0%	60,000	60,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	70,000	70,000	0.0%	70,000	70,000	0.0%	70,000	70,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	80,000	80,000	0.0%	80,000	80,000	0.0%	80,000	80,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	90,000	90,000	0.0%	90,000	90,000	0.0%	90,000	90,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	100,000	100,000	0.0%	100,000	100,000	0.0%	100,000	100,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	110,000	110,000	0.0%	110,000	110,000	0.0%	110,000	110,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	120,000	120,000	0.0%	120,000	120,000	0.0%	120,000	120,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	130,000	130,000	0.0%	130,000	130,000	0.0%	130,000	130,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	140,000	140,000	0.0%	140,000	140,000	0.0%	140,000	140,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	150,000	150,000	0.0%	150,000	150,000	0.0%	150,000	150,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	160,000	160,000	0.0%	160,000	160,000	0.0%	160,000	160,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	170,000	170,000	0.0%	170,000	170,000	0.0%	170,000	170,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	180,000	180,000	0.0%	180,000	180,000	0.0%	180,000	180,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	190,000	190,000	0.0%	190,000	190,000	0.0%	190,000	190,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	200,000	200,000	0.0%	200,000	200,000	0.0%	200,000	200,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	210,000	210,000	0.0%	210,000	210,000	0.0%	210,000	210,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	220,000	220,000	0.0%	220,000	220,000	0.0%	220,000	220,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	230,000	230,000	0.0%	230,000	230,000	0.0%	230,000	230,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	240,000	240,000	0.0%	240,000	240,000	0.0%	240,000	240,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	250,000	250,000	0.0%	250,000	250,000	0.0%	250,000	250,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	260,000	260,000	0.0%	260,000	260,000	0.0%	260,000	260,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	270,000	270,000	0.0%	270,000	270,000	0.0%	270,000	270,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	280,000	280,000	0.0%	280,000	280,000	0.0%	280,000	280,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	290,000	290,000	0.0%	290,000	290,000	0.0%	290,000	290,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	300,000	300,000	0.0%	300,000	300,000	0.0%	300,000	300,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	310,000	310,000	0.0%	310,000	310,000	0.0%	310,000	310,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	320,000	320,000	0.0%	320,000	320,000	0.0%	320,000	320,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	330,000	330,000	0.0%	330,000	330,000	0.0%	330,000	330,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	340,000	340,000	0.0%	340,000	340,000	0.0%	340,000	340,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	350,000	350,000	0.0%	350,000	350,000	0.0%	350,000	350,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	360,000	360,000	0.0%	360,000	360,000	0.0%	360,000	360,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	370,000	370,000	0.0%	370,000	370,000	0.0%	370,000	370,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	380,000	380,000	0.0%	380,000	380,000	0.0%	380,000	380,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	390,000	390,000	0.0%	390,000	390,000	0.0%	390,000	390,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	400,000	400,000	0.0%	400,000	400,000	0.0%	400,000	400,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	410,000	410,000	0.0%	410,000	410,000	0.0%	410,000	410,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	420,000	420,000	0.0%	420,000	420,000	0.0%	420,000	420,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	430,000	430,000	0.0%	430,000	430,000	0.0%	430,000	430,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	440,000	440,000	0.0%	440,000	440,000	0.0%	440,000	440,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	450,000	450,000	0.0%	450,000	450,000	0.0%	450,000	450,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	460,000	460,000	0.0%	460,000	460,000	0.0%	460,000	460,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	470,000	470,000	0.0%	470,000	470,000	0.0%	470,000	470,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	480,000	480,000	0.0%	480,000	480,000	0.0%	480,000	480,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	490,000	490,000	0.0%	490,000	490,000	0.0%	490,000	490,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	500,000	500,000	0.0%	500,000	500,000	0.0%	500,000	500,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	510,000	510,000	0.0%	510,000	510,000	0.0%	510,000	510,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	520,000	520,000	0.0%	520,000	520,000	0.0%	520,000	520,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	530,000	530,000	0.0%	530,000	530,000	0.0%	530,000	530,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	540,000	540,000	0.0%	540,000	540,000	0.0%	540,000	540,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	550,000	550,000	0.0%	550,000	550,000	0.0%	550,000	550,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	560,000	560,000	0.0%	560,000	560,000	0.0%	560,000	560,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	570,000	570,000	0.0%	570,000	570,000	0.0%	570,000	570,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	580,000	580,000	0.0%	580,000	580,000	0.0%	580,000	580,000	0.0%
Other	10,000	10,000	0.0%	10,000	10,000	0.0%	10,000	10,000	0.0%
State & Federal	590,000	590,000	0.0%	590,000	590,000	0.0%	590,000	590,000	0.0%
Other	10,000								

Academy Sports and Outdoors, Inc. (ASO.O) – Expect Slight 4Q Beat on Stronger Comps/Weaker GM and F25 Guidance Below Consensus

We expect a slight 4Q24 EPS beat (BMO 3/20) driven by stronger comps, partially offset by weaker GM. We anticipate mgmt will guide F25 adj EPS to \$5.50-6.50 (vs cons \$6.58) based on comps -LSD to +LSD (cons +0.8%). We expect more detail around the launch of new NKE product in April, which mgmt expects to move the needle on sales. We believe weaker near-term trends and macro/tariff uncertainty could push out any potential comp inflection to 2Q at the earliest (2Q is the easiest comparison given logistics issues LY) and investors would largely remain skeptical given macro uncertainty. However, shares trade at F25E P/E multiple of just 7.5x, suggesting a lot of pessimism is already priced-in. Any signs of comps improving

from its down MSD run-rate over last 3-yrs will be viewed positively. Despite our positive 12-month view and Buy rating, we see a balanced risk/reward into 4Q EPS.

[Paul Lejuez, CFA, CPA](#)

Citi vs Consensus

	4Q24E		1Q25E		F24E		F25E	
	Citi Ests	Consensus	Citi Ests	Consensus	Citi Ests	Consensus	Citi Ests	Consensus
Sales	\$1,700	\$1,674	\$1,375	\$1,412	\$5,957	\$5,933	\$6,184	\$6,255
% YoY	(5.3%)	(6.7%)	0.8%	3.5%	(3.3%)	(3.7%)	3.8%	5.0%
Comp	(2.5%)	(4.3%)	(3.0%)	(0.4%)	(4.9%)	(5.4%)	(0.6%)	0.8%
Gross profit	\$569	\$568	\$453	\$479	\$2,041	\$2,039	\$2,104	\$2,164
% margin	33.5%	33.9%	32.9%	33.9%	34.3%	34.4%	34.0%	34.6%
SG&A	\$392	\$393	\$361	\$362	\$1,459	\$1,463	\$1,540	\$1,547
% YoY	(0.7%)	(0.4%)	3.9%	4.3%	3.6%	3.9%	5.5%	6.0%
EBIT	\$177	\$172	\$92	\$113	\$582	\$577	\$564	\$615
% margin	10.4%	10.3%	6.7%	8.0%	9.8%	9.7%	9.1%	9.8%
EPS	\$1.86	\$1.84	\$0.92	\$1.17	\$5.94	\$5.91	\$6.00	\$6.58
% YoY	-15.7%	-16.6%	-14.3%	8.9%	-14.7%	-15.1%	0.9%	10.8%

Industry

[Global FinTech and Payments – Travel Spend: Checking into QTD Travel Trends; V/MA Commentary; X-Border ex Intra-Europe Decelerates](#)

We perform a timely check into travel trends, given consumer spend uncertainty. Through March 9, 1QTD global flight growth (y/y) decelerated slightly from 4Q. Cross-border ex intra-Europe remains stable in the 8.5-9% range, though trends decelerated throughout the quarter from the ~9%-11% y/y range in January to ~6%-8% in February and March weeks. While Visa and Mastercard noted relatively stable spend trends overall through February (ex. Leap Year), we are watching the cross-border monthly exit rate for Jun-quarter/forward implications given deceleration and consumer/business uncertainty. U.S. domestic flight activity has shown modest improvement – from -1% y/y through the first week in February to ~1-2% thereafter. However, U.S. airlines have voiced trend uncertainty and the first week in March showed a deceleration. **Details Below & Inside.**

[Andrew Schmidt](#)

[Retail Weekend Reading – The 10 Quotes that Stood Out from Citi’s Global Consumer/Retail Conference](#)

We hosted 24 companies from our combined retail universe (ANF, AAP, AS, AZO, BBY, BIRK, BJ, BURL, CRI, COLM, FND, HBI, LEVI, LOW, M, OXM, RL, TPR, TGT, TJX, TSCO, URBN, VVV, and WMT) at Citi’s Global Consumer Conference in Miami (Aventura), Florida on March 9-11 and were able to sit in on many meetings. In this note, we highlight 10 of the most interesting/noteworthy quotes we heard from our meetings at the conference that have broader implications across the retail landscape. We include the quote below and provide more detail inside.

[Paul Lejuez, CFA, CPA](#) | [Steven Zacccone, CFA](#)


[US Industrial Conglomerates – Jan ‘25 AHRI Data: Positive \(But Nuanced\) Across Resi Water Heaters, Commercial Water Heaters, and HVAC](#)

Jan. ’25 U.S. AHRI Data reveals positive (but nuanced) results across residential water heater shipments (+0.9% YoY), commercial water heater shipments (+5.0% YoY), and HVAC shipments (+29.9% YoY). Residential water heater YoY shipments continue to face pressure that we think reflects a challenging demand environment amid still elevated interest rates/weaker housing market activity. Total commercial water heaters YoY shipments improved, although Jan ‘25. AHRI data suggests mixed performance with commercial gas heater shipments down (-3.2% YoY) while commercial electric heaters grew (+10.0% YoY), which we think is driven by energy-efficiency trends. HVAC recorded solid YoY growth reflecting easy

comps (albeit off the easiest comp of the year with Jan '24 -21.3%) as well as likely still some pre-buy in resi-HVAC (+32.5% YoY); in commercial-HVAC, despite a tougher comp (Jan '25 -22.5% YoY vs. Jan '24 +20.8%), we think commercial-HVAC remains reasonably healthy with datacenter-related demand likely being a growing contributor.

Andrew Kaplowitz

U.S. Factory Shipments of Air-Conditioners & Heat Pumps (YoY%)




Global Shipping - Weekly Update - Divergence in Air Freight Rate

We update our weekly freight data tracker, which covers both sea and air freight. We see capacity growth of +19% YoY in April (vs +22% in March). Meanwhile, air freight rates growth is at +1.5% YoY in March (vs. +5% YoY in February).

Kaseedit Choonawat | Chloe Fu

(Europe-N.America) Air Freight Rate (\$/kg)



(Asia-Europe) Air Freight Rate (\$/kg)



North America Chemicals - Examining Most/Least Crowded Stocks; Little Love for Petchems

Analysis from Citi's Quant Team suggests LIN, DD, and ECL are the most crowded names in NA chemicals, while APD, OLN, and CE are the least crowded. Over the last month, PPG, DD, and FMC have seen the largest increase in crowding score, while ALB, AXTA, and EMN have seen the largest decrease (Figure 1).

Patrick Cunningham

Citi NA Chemicals Long Crowding Composite

High Ranking =	Higher Crowding	Growth	Expensive	Lower Short Interest	Positive Sentiment	Higher Macro
----------------	-----------------	--------	-----------	----------------------	--------------------	--------------


Company	Crowding		Hist. Relative				Previous	M/M
	Composite	Quant Factor	Valuation	Short Interest	Sentiment Rank	Macro Risk Contribution	Crowding Composite	Crowding Change
Linde	95.6%	35.9%	72.5%	94.3%	67.1%	88.9%	90.2%	5.4%
DuPont de Nemours	92.5%	35.2%	44.7%	89.9%	92.0%	82.0%	76.9%	15.6%
Ecolab Inc	92.0%	46.4%	53.4%	89.4%	78.3%	74.2%	78.9%	13.1%
Sherwin-Williams	61.0%	65.7%	56.4%	6.1%	52.8%	87.9%	77.2%	-16.3%
Westlake Chemical	59.5%	22.1%	59.2%	60.1%	31.5%	93.2%	72.4%	-12.9%
International Flavors & Fragrances	53.5%	4.8%	35.3%	92.8%	75.0%	48.1%	42.5%	11.0%
Huntsman Corp	52.9%	13.9%	49.8%	84.9%	17.7%	88.7%	52.9%	-0.1%
Axalta Coating Systems	45.6%	62.8%	20.9%	27.2%	37.7%	95.5%	67.8%	-22.2%
Corteva	42.4%	42.3%	61.3%	6.9%	74.2%	54.4%	45.2%	-2.7%
H.B. Fuller	36.5%	44.7%	17.0%	59.0%	15.8%	91.1%	25.2%	11.3%
Dow Inc	32.4%	6.9%	41.6%	21.5%	57.0%	92.8%	19.2%	13.2%
PPG Industries	30.9%	24.8%	17.1%	51.8%	27.7%	95.7%	10.2%	20.7%
Eastman Chemical	19.3%	30.6%	38.7%	7.6%	18.7%	98.0%	39.2%	-19.9%
Ecovyst	17.5%	40.3%	24.5%	4.9%	69.8%	50.3%	8.2%	9.3%
FMC	14.9%	24.6%	6.6%	51.7%	56.2%	44.1%	0.6%	14.3%
Albemarle Corp	7.5%	12.8%	38.8%	24.6%	6.6%	74.5%	42.5%	-35.1%
Celanese Corp	6.4%	16.5%	14.1%	32.6%	9.2%	79.2%	9.9%	-3.5%
Olin	6.1%	19.4%	37.4%	21.6%	13.6%	56.3%	24.7%	-18.6%
Air Products & Chemicals	3.3%	21.5%	36.7%	0.1%	23.9%	47.9%	13.6%	-10.4%

US Restaurants - Setting the Table for the Week: Store Footprints and Traffic – SG and CAVA


It was a volatile week for restaurant stocks as investors grew more worried about the health of the US consumer. The tone from companies at Citi's Annual [Global Consumer Conference](#) this past week did not match this concern, in our view. Below, we dig into a discussion topic (traffic growth vs. store footprints) for 2 companies that were in attendance (SG and CAVA).

Jon Tower, CFA | Karen Holthouse, CFA | Gautam Nanda

CAVA and SG store bases vs. population density – pre-4Q23 (old)



SG store base pre-(old) and post (new)-4Q23 vs. population density



Economics & Strategy

PULSE Monitor - Revisions Sour

Revisions are breaking down, worse than seasonal trends. However, because of index composition and the magnitude of revisions, we still have not seen full-year 2025 estimates move lower. But we are starting to see the first instances of analysts cutting numbers on tariff impacts. Anecdotally, we are seeing analysts in certain stocks, particularly consumer, moving estimates lower within the guidance ranges announced by corporates during the most recent reporting period. Still, we feel that tariff impacts are not well reflected in guidance (outside of some cautiousness despite strong Q4 results) or consensus estimates. Therefore, we may see a wave of negative pre-announcements over the next three weeks, particularly for companies with China COGS exposure given roughly half the quarter was exposed to increased tariffs.

Scott T Chronert | Drew Pettit | Patrick Galvin, CFA


Measuring the Crowded Trade in Global Equities - Sector crowding mostly steady despite volatility

Overall sector crowding trends across regions held steady so far since last month, despite the volatility and large index level declines. The crowding trend remains

delineated between Cyclical on one end (crowded) and Defensive on the other. However, some shifting is more noticeable among sectors in Europe where the equity markets are now outperforming the US (YTD), particularly in Financials which has become the most crowded sector there. Defensive Utilities and Consumer Staples are no longer extremely under-crowded in Europe, while Real Estate has seen its crowding increase.

Richard W Schlatter | Hong Li | Anju Bhandari | Chris Montagu | Chris Ma

Aggregate Sector Crowding (MSCI)




US Economics - UMich inflation expectations jump higher again

University of Michigan consumer sentiment index fell more than expected again in March to 57.9 from 64.7. Most of the decline was driven by the expectations index. Inflation expectations jumped substantially higher again this month with 1y inflation expectations increasing to 4.9% from 4.3% and 5-10y inflation expectations increasing to 3.9% from 3.5%. While there are some reasons to take these readings with a grain of salt, this could still be an uncomfortable reading for at least some Fed officials. We think most Fed officials will not necessarily be too concerned by U Mich longer-term inflation expectations as some consumer inflation expectations measures like the NY Fed ones have been well behaved and market-based measures have also not picked up.

Gisela Young | Andrew Hollenhorst | Veronica Clark

There is political divide in inflation expectations



US Economics – FOMC Preview – Risks skew dovish

Fed officials are likely to take a modest dovish step on March 19th with the median “dot” shifting down to show 75bp rather than 50bp of total rate cuts in 2025 in our base case. Stubborn inflation in January and February and the rise in inflation expectations limits the extent of the dovish move and rates will likely stay on-hold at this meeting. But by the May FOMC meeting officials will likely conclude that downside growth risks predominate and begin a new series of rate cuts.

Andrew Hollenhorst | Veronica Clark

Citi Expectations for March Summary of Economic Projections


		2025	2026	2027	LR
Real GDP	Mar	1.7	2.0	1.9	1.8
	Dec	2.1	2.0	1.9	1.8
Unemployment rate	Mar	4.3	4.3	4.3	4.2
	Dec	4.3	4.3	4.3	4.2
PCE inflation	Mar	2.6	2.2	2.0	2.0
	Dec	2.5	2.1	2.0	2.0
Core PCE inflation	Mar	2.6	2.2	2.0	2.0
	Dec	2.5	2.2	2.0	
Federal funds rate	Mar	3.6	3.1	3.1	3.0
	Dec	3.9	3.4	3.1	3.0

Canada Economics Weekly – Tariffs are dovish for the BoC

The BoC lowered its policy rate again this week, reacting to the start of tariffs on some Canadian exports last week and the substantial uncertainty around tariffs causing businesses and households to cut back on spending plans. Governor Macklem again highlighted that policy must weigh the upside risks to inflation from tariff developments with the downside risks from softer growth. Many would interpret this as a relatively hawkish stance from the BoC. But the fact that a rate cut would likely not have occurred this week if not for tariffs should tell markets that tariffs are a near-term dovish development for the BoC. We continue to expect 25bp cuts at the next three meetings to 2%. While we are less certain around the exact meeting-by-meeting path, we are more confident that the destination for policy rates this year is a bit below neutral, if not lower.

Veronica Clark | Gisela Young

High frequency data could be an early signal of any labor market weakening




Fixed Income & FX

US Rates Weekly - Bearish risks rising

We expect yields to move higher in the medium term as inflation concerns persist. The risk of foreign sales of US assets as a response to tariffs and changes in geopolitical alliances is also worth bearing in mind.

Jabaz Mathai | Jason Williams | Mike Chang | Raghav Datla | Alejandra Vazquez Plata

CPI came in lower than fixings market pricing (see Mar-25 below); however, y/y core services ex shelter is still inflating at 3.75%.





Global Credit Derivatives Strategy - Braver, Newer World

European risk assets continue their impressive run of outperformance vs their US counterparts. iTraxx Main can see further upside from broad sector compression vs CDX IG. We entered 2025 preferring Main to IG due to diverging monetary policy. Today, however, we see renewed animal spirits in Europe and a faltering US as reasons to prefer Main even if relative monetary policy trends fail to deliver what we expected.

Philip Dobrinov

iTraxx Main Continues Impressive Run vs CDX IG

Continued Compression Coming from More than Wider Financials



Upcoming Releases of Economic Indicators

Date	Time	Report	Citi	Median	High	Low	Prior
3/17/2025	8:30	Empire Manufacturing (Mar)		-2	5	-8	5.7
		Retail Sales Advance MoM (Feb)	0.7%	0.7%	1.0%	0.3%	-0.9%
		Retail Sales Ex Auto MoM (Feb)	0.5%	0.4%	0.9%	0.0%	-0.4%
		Retail Sales Ex Auto and Gas (Feb)	0.7%	0.5%	1.0%	-0.1%	-0.5%
		Retail Sales Control Group (Feb)	0.9%	0.3%	0.9%	-0.5%	-0.8%
	10:00	Business Inventories (Jan)		0.30%	0.70%	0.10%	-0.20%
3/18/2025	8:30	NAHB Housing Market Index (Mar)		42	44	40	42
		Housing Starts (Feb)	1417k	1375k	1415k	1300k	1366k
		Housing Starts MoM (Feb)	3.7%	0.7%	3.6%	-4.8%	-9.8%
		Building Permits (Feb P)	1458k	1450k	1483k	1390k	1473k
		Building Permits MoM (Feb P)	-1.0%	-1.6%	0.7%	-5.6%	-0.6%
		Import Price Index MoM (Feb)		-0.10%	0.10%	-0.30%	0.30%
		Import Price Index ex Petroleum MoM (Feb)		0.10%	0.20%	0.00%	0.10%
		Import Price Index YoY (Feb)					1.90%
		Export Price Index MoM (Feb)		-0.30%	1.30%	-0.70%	1.30%
		Export Price Index YoY (Feb)					2.70%
		New York Fed Services Business Activity (Mar)					-10.5
	9:15	Industrial Production MoM (Feb)	0.0%	0.20%	0.50%	-0.30%	0.50%
		Capacity Utilization (Feb)	77.8%	77.8%	78.0%	77.4%	77.8%
		Manufacturing (SIC) Production (Feb)	0.3%	0.2%	0.5%	0.0%	-0.1%
3/19/2025	7:00	MBA Mortgage Applications (14-Mar)					11.20%
	14:00	FOMC Rate Decision (Upper Bound) (19-Mar)	4.50%	4.50%	4.50%	4.50%	4.50%
		FOMC Rate Decision (Lower Bound) (19-Mar)	4.25%	4.25%	4.25%	4.25%	4.25%
		Fed Interest on Reserve Balances Rate (20-Mar)					4.40%
		FOMC Median Rate Forecast: Current Yr (19-Mar)					4.38%
		FOMC Median Rate Forecast: Next Yr (19-Mar)					3.88%
		FOMC Median Rate Forecast: +2 Yrs (19-Mar)					3.38%
		FOMC Median Rate Forecast: Long-Run (19-Mar)					3.00%
	16:00	Net Long-term TIC Flows (Jan)					\$72.0b
		Total Net TIC Flows (Jan)					\$87.1b
3/20/2025	8:30	Current Account Balance (4Q)		-\$334.0b	-\$301.3b	-\$340.0b	-\$310.9b
		Initial Jobless Claims (15-Mar)	222k	225k	230k	219k	220k
		Continuing Claims (8-Mar)	1888k				1870k
		Philadelphia Fed Business Outlook (Mar)		8	24	-5	18.1
	10:00	Leading Index (Feb)		-0.30%	-0.10%	-0.40%	-0.30%
		Existing Home Sales (Feb)	4.1m	3.94m	4.10m	3.88m	4.08m
		Existing Home Sales MoM (Feb)	0.5%	-3.4%	0.5%	-4.9%	-4.9%

Events

3/08/2025-3/20/2025		Fed's External Communications Blackout
3/19/2025	14:00	FOMC Rate Decision (Upper Bound)
3/19/2025	14:00	FOMC Rate Decision (Lower Bound)
3/21/2025	9:05	Fed's Williams Speaks in Bahamas

© 2025 Citigroup Inc. No redistribution without Citigroup's written permission.

Sources: Citi Research, Bloomberg.

Key Rating and Target Price Changes

Company	Ccy	Closing Price	Rating			Target Price			Analyst	Report
			New	Prior	Chg	New	Prior	Chg		
Agco Corporation (AGCO.N)	US\$	93.84	nc	Neutral		98.00	95.00	▲	Kyle Menges	Report
APA Corp (APA.O)	US\$	19.61	nc	Neutral		20.00	24.00	▼	Scott Gruber	Report
Academy Sports and Outdoors, Inc. (ASO.O)	US\$	45.10	nc	Buy		60.00	65.00	▼	Paul Lejuez, CFA, CPA	Report
Crown Castle Inc (CCI.N)	US\$	103.22	nc	Buy		108.00	106.00	▲	Michael Rollins, CFA	Report
Cushman & Wakefield (CWK.N)	US\$	10.69	nc	Neutral		12.00	16.00	▼	Nick Joseph	Report
Devon Energy Corp (DVN.N)	US\$	34.55	nc	Buy		46.00	48.00	▼	Scott Gruber	Report
Emerson Electric Co. (EMR.N)	US\$	111.93	Buy	Rating Suspended		132.00	na		Andrew Kaplowitz	Report
EOG Resources Inc (EOG.N)	US\$	123.92	nc	Neutral		125.00	134.00	▼	Scott Gruber	Report
EQT Corporation (EQT.N)	US\$	50.72	nc	Buy		60.00	51.00	▲	Scott Gruber	Report
Diamondback Energy, Inc. (FANG.O)	US\$	150.20	nc	Neutral		157.00	195.00	▼	Scott Gruber	Report
Host Hotels & Resorts (HST.O)	US\$	14.91	nc	Buy		19.00	21.00	▼	Nick Joseph	Report
Kimco Realty Corp (KIM.N)	US\$	20.58	nc	Neutral		21.00	27.00	▼	Nick Joseph	Report
Kohl's (KSS.N)	US\$	8.06	nc	Neutral		8.00	11.00	▼	Paul Lejuez, CFA, CPA	Report
Occidental Petroleum Corp (OXY.N)	US\$	46.53	nc	Neutral		51.00	56.00	▼	Scott Gruber	Report
Terex Corporation (TEX.N)	US\$	40.31	nc	Neutral		45.00	48.00	▼	Kyle Menges	Report
Trivago NV (TRVG.O)	US\$	4.12	nc	Neutral		4.50	2.60	▲	Ronald Josey	Report
Ulta Beauty Inc. (ULTA.O)	US\$	357.48	nc	Neutral		365.00	405.00	▼	Kelly Crago, CFA	Report

nc = no change H = High Risk

Any price(s) of instruments mentioned in recommendations are as of the prior day's market close on the primary market for the instrument, unless otherwise stated.

Refer to the Report for the date and details regarding the rating and/or target price change.

Source: Citi Research

If you are visually impaired and would like to speak to a Citi representative regarding the details of the graphics in this document, please call USA 1-888-800-5008 (TTY: 711), from outside the US +1-210-677-3788

Appendix A-1

ANALYST CERTIFICATION

The research analysts primarily responsible for the preparation and content of this research report are either (i) designated by "AC" in the author block or (ii) listed in bold alongside content which is attributable to that analyst. If multiple AC analysts are designated in the author block, each analyst is certifying with respect to the entire research report other than (a) content attributable to another AC certifying analyst listed in bold alongside the content and (b) views expressed solely with respect to a specific issuer which are attributable to another AC certifying analyst identified in the price charts or rating history tables for that issuer shown below. Each of these analysts certify, with respect to the sections of the report for which they are responsible: (1) that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc. and its affiliates; and (2) no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in this report.

IMPORTANT DISCLOSURES

This product merely summarizes previously published research notes. To access the complete report along with the associated Analyst Certification, Issuer- or Analyst-specific Disclosures and non-US research analyst disclosures please click on the hyperlink alongside or in the headline of each excerpt above.

Analysts' compensation is determined by Citi Research management and Citigroup's senior management and is based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates (the "Firm"). Compensation is not linked to specific transactions or recommendations. Like all Firm employees, analysts receive compensation that is impacted by overall Firm profitability which includes investment banking, sales and trading, and principal trading revenues. One factor in equity research analyst compensation is arranging corporate access events between institutional clients and the management teams of covered companies. Typically, company management is more likely to participate when the analyst has a positive view of the company.

For financial instruments recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in such financial instruments (and any underlying instruments) and may act as principal in connection with transactions in such instruments. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Unless stated otherwise neither the Research Analyst nor any member of their team has viewed the material operations of the Companies for which an investment view has been provided within the past 12 months.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Research product ("the Product"), please contact Citi Research, 388 Greenwich Street, 6th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Pursuant to the Market Abuse Regulation a history of all Citi Research recommendations published during the preceding 12-month period can be accessed via Citi Velocity (<https://www.citivelocity.com/cv2>) or your standard distribution portal. Historical disclosures (for up to the past three years) will be provided upon request.

Citi Research Equity Ratings Distribution

Data current as of 01 Jan 2025	12 Month Rating			Catalyst Watch		
	Buy	Hold	Sell	Buy	Hold	Sell
Citi Research Global Fundamental Coverage (Neutral=Hold)	57%	34%	9%	35%	48%	17%
% of companies in each rating category that are investment banking clients	43%	44%	35%	47%	40%	42%

Guide to Citi Research Fundamental Research Investment Ratings:

Citi Research stock recommendations include an investment rating and an optional risk rating to highlight high risk stocks.

Risk rating takes into account both price volatility and fundamental criteria. Stocks will either have no risk rating or a High risk rating assigned.

Investment Ratings: Citi Research investment ratings are Buy, Neutral and Sell. Our ratings are a function of analyst expectations of expected total return ("ETR") and risk. ETR is the sum of the forecast price appreciation (or depreciation) plus the dividend yield for a stock within the next 12 months. The target price is based on a 12 month time horizon. The Investment rating definitions are: Buy (1) ETR of 15% or more or 25% or more for High risk stocks; and Sell (3) for negative ETR. Any covered stock not assigned a Buy or a Sell is a Neutral (2). For stocks rated Neutral (2), if an analyst believes that there are insufficient

valuation drivers and/or investment catalysts to derive a positive or negative investment view, they may elect with the approval of Citi Research management not to assign a target price and, thus, not derive an ETR. Citi Research may suspend its rating and target price and assign "Rating Suspended" status for regulatory and/or internal policy reasons. Citi Research may also suspend its rating and target price and assign "Under Review" status for other exceptional circumstances (e.g. lack of information critical to the analyst's thesis, trading suspension) affecting the company and/or trading in the company's securities. In both such situations, the rating and target price will show as "—" and "—" respectively in the rating history price chart. Prior to 11 April 2022 Citi Research assigned "Under Review" status to both situations and prior to 11 Nov 2020 only in exceptional circumstances. As soon as practically possible, the analyst will publish a note re-establishing a rating and investment thesis. Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

Catalyst Watch/Short Term Views ("STV") Ratings Disclosure:

Catalyst Watch and STV Upside/Downside calls: Citi Research may also include a Catalyst Watch or STV Upside or Downside call to indicate the analyst expects the share price to rise (fall) in absolute terms over a specified period of 30 or 90 days in reaction to one or more specific near-term catalysts or events impacting the company or the market. A Catalyst Watch will be published when Analyst confidence is high that an impact to share price will occur; it will be a STV when confidence level is moderate. A Catalyst Watch or STV Upside/Downside call will automatically expire at the end of the specified 30/90 day period (though only a Catalyst Watch expiration will generate a published research note). The Catalyst Watch will also be automatically removed with a published research note if share price performance (calculated at market close) exceeds 15% against the direction of the call (unless over-ridden by the analyst). The analyst may also remove a Catalyst Watch or STV call prior to the end of the specified period in a published research note. A Catalyst Watch/STV Upside or Downside call may be different from and does not affect a stock's fundamental equity rating, which reflects a longer-term total absolute return expectation. For purposes of FINRA ratings-distribution-disclosure rules, a Catalyst Watch/STV Upside call corresponds to a buy recommendation and a Catalyst Watch/STV Downside call corresponds to a sell recommendation. Any stock not assigned to a Catalyst Watch Upside, Catalyst Watch Downside, STV Upside, or STV Downside call is considered Catalyst Watch/STV No View. For purposes of FINRA ratings distribution-disclosure rules, we correspond Catalyst Watch/STV No View to Hold in our ratings distribution table for our Catalyst Watch/STV Upside/Downside rating system. However, we reiterate that we do not consider No View to be a recommendation. For all Catalyst Watch/STV Upside/Downside calls, risk exists that the catalyst(s) and associated share-price movement will not materialize as expected.

OTHER DISCLOSURES

Any price(s) of instruments mentioned in recommendations are as of the prior day's market close on the primary market for the instrument, unless otherwise stated.

The completion and first dissemination of any recommendations made within this research report are as of the Eastern date-time displayed at the top of the Product. If the Product references views of other analysts then please refer to the price chart or rating history table for the date/time of completion and first dissemination with respect to that view.

Regulations in various jurisdictions require that where a recommendation differs from any of the author's previous recommendations concerning the same financial instrument or issuer that has been published during the preceding 12-month period that the change(s) and the date of that previous recommendation are indicated. For fundamental coverage please refer to the price chart or rating change history within this disclosure appendix or the issuer disclosure summary at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

Citi Research has implemented policies for identifying, considering and managing potential conflicts of interest arising as a result of publication or distribution of investment research. A description of these policies can be found at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

The proportion of all Citi Research recommendations that were the equivalent to "Buy", "Hold", "Sell" at the end of each quarter over the prior 12 months (with the % of these that had received investment firm services from Citi in the prior 12 months shown in brackets) is as follows: Q4 2024 Buy 32% (64%), Hold 44% (52%), Sell 23% (44%), RV 0.4% (92%); Q3 2024 Buy 33% (61%), Hold 44% (52%), Sell 23% (49%), RV 0.4% (80%); Q2 2024 Buy 33% (61%), Hold 44% (52%), Sell 23% (48%), RV 0.5% (90%); Q1 2024 Buy 32% (62%), Hold 44% (52%), Sell 23% (48%), RV 0.5% (88%). For the purposes of disclosing recommendations other than for equity (whose definitions can be found in the corresponding disclosure sections), "Buy" means a positive directional trade idea; "Sell" means a negative directional trade idea; and "Relative Value" means any trade idea which does not have a clear direction to the investment strategy.

European regulations require a 5 year price history when past performance of a security is referenced. CitiVelocity's Charting Tool (https://www.citivelocity.com/cv2/#go/CHARTING_3_Equities) provides the facility to create customisable price charts including a five year option. This tool can be found in the Data & Analytics section under any of the asset class menus in CitiVelocity (<https://www.citivelocity.com/>). For further information contact CitiVelocity support (https://www.citivelocity.com/cv2/go/CLIENT_SUPPORT). The source for all referenced prices, unless otherwise stated, is DataCentral, which sources price information from Thomson Reuters. Past performance is not a guarantee or reliable indicator of future results. Forecasts are not a guarantee or reliable indicator of future performance.

Investors should always consider the investment objectives, risks, and charges and expenses of an ETF carefully before investing. The applicable prospectus and key investor information document (as applicable) for an ETF should contain this and other information about such ETF. It is important to read carefully any such prospectus before investing. Clients may obtain prospectuses and key investor information documents for ETFs from the applicable distributor or authorized participant, the

exchange upon which an ETF is listed and/or from the applicable website of the applicable ETF issuer. The value of the investments and any accruing income may fall or rise. Any past performance, prediction or forecast is not indicative of future or likely performance. Any information on ETFs contained herein is provided strictly for illustrative purposes and should not be deemed an offer to sell or a solicitation of an offer to purchase units of any ETF either explicitly or implicitly. The opinions expressed are those of the authors and do not necessarily reflect the views of ETF issuers, any of their agents or their affiliates. Citigroup Global Markets India Private Limited and/or its affiliates may have, from time to time, actual or beneficial ownership of 1% or more in the debt securities of the subject issuer.

Please be advised that pursuant to Executive Order 13959 as amended (the "Order"), U.S. persons are prohibited from investing in securities of any company determined by the United States Government to be the subject of the Order. This research is not intended to be used or relied upon in any way that could result in a violation of the Order. Investors are encouraged to rely upon their own legal counsel for advice on compliance with the Order and other economic sanctions programs administered and enforced by the Office of Foreign Assets Control of the U.S. Treasury Department.

This communication is directed at persons who are "Eligible Clients" as such term is defined in the Israeli Regulation of Investment Advice, Investment Marketing and Investment Portfolio Management law, 1995 (the "Advisory Law"). Within Israel, this communication is not intended for retail clients and Citi will not make such products or transactions available to retail clients or to non-Eligible Clients. The presenter is not licensed as investment advisor or investment marketer by the Israeli Securities Authority ("ISA") and this communication does not constitute investment or marketing advice. The information contained herein may relate to matters that are not regulated by the ISA. Any securities which are the subject of this communication may not be offered or sold to any Israeli person except pursuant to a security offering exemption according to the Israeli Securities Law, 1968 and the public offering rules provided thereunder.

Citi Research broadly and simultaneously disseminates its research content to the Firm's institutional and retail clients via the Firm's proprietary electronic distribution platforms (e.g., Citi Velocity and various Global Wealth platforms). As a convenience, certain, but not all, research content may be distributed through third party aggregators. Clients may receive published research reports by email, on a discretionary basis, and only after such research content has been broadly disseminated. Certain research is made available only to institutional investors to satisfy regulatory requirements. The level and types of services provided by Citi Research analysts to clients may vary depending on various factors such as the client's individual preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with the Firm and legal and regulatory constraints.

Pursuant to Comissão de Valores Mobiliários Resolução 20 and ASIC Regulatory Guide 264, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Disclosure for investors in the Republic of Turkey: Under Capital Markets Law of Turkey (Law No: 6362), the investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided in accordance with a contract of engagement on investment advisory concluded between brokerage houses, portfolio management companies, non-deposit banks and clients. Comments and recommendations stated here rely on the individual opinions of the ones providing these comments and recommendations. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations. Furthermore, Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies and/or trades on securities covered in this research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report, however investors should also note that the Firm has in place organisational and administrative arrangements to manage potential conflicts of interest of this nature.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. Statements and views concerning ESG (environmental, social, governance) factors are typically based upon public statements made by the affected company or other public news, which the author may not have independently verified. ESG factors are one consideration that investors may choose to examine when making investment decisions. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Research does not set a predetermined frequency for publication, if the Product is a fundamental equity or credit research report, it is the intention of Citi Research to provide research coverage of the covered issuers, including in response to news affecting the issuer. For non-fundamental research reports, Citi Research may not

provide regular updates to the views, recommendations and facts included in the reports. Notwithstanding that Citi Research maintains coverage on, makes recommendations concerning or discusses issuers, Citi Research may be periodically restricted from referencing certain issuers due to legal or policy reasons. Where a component of a published trade idea is subject to a restriction, the trade idea will be removed from any list of open trade ideas included in the Product. Upon the lifting of the restriction, the trade idea will either be re-instated in the open trade ideas list if the analyst continues to support it or it will be officially closed. Citi Research may provide different research products and services to different classes of customers (for example, based upon long-term or short-term investment horizons) that may lead to differing conclusions or recommendations that could impact the price of a security contrary to the recommendations in the alternative research product, provided that each is consistent with the rating system for each respective product.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by.

The Product is made available in **Australia** through Citigroup Global Markets Australia Pty Limited. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. Citigroup Global Markets Australia Pty Limited is not an Authorised Deposit-Taking Institution under the Banking Act 1959, nor is it regulated by the Australian Prudential Regulation Authority.

The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários ("CVM"), BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBIMA - Associação Brasileira das Entidades dos Mercados Financeiro e de Capitais. Av. Paulista, 1111 - 14º andar(parte) - CEP: 01311920 - São Paulo - SP.

This Product is available in **Chile** through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Comisión Para El Mercado Financiero. Agustinas 975, piso 2, Santiago, Chile.

Disclosure for investors in the Republic of Colombia :This communication or message does not constitute a professional recommendation to make investment in the terms of article 2.40.1.1.2 of Decree 2555 de 2010 or the regulations that modify, substitute or complement it. Para la elaboración y distribución de informes de investigación y de comunicaciones generales de que trata este artículo no se requiere ser una entidad vigilada por la Superintendencia Financiera de Colombia.

The Product is made available in **Germany** by Citigroup Global Markets Europe AG ("CGME"), which is regulated by the European Central Bank and the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht BaFin). Börsenplatz 9, 60313 Frankfurt am Main, Germany.

Unless otherwise specified, if the analyst who prepared this report is based in Hong Kong and it relates to "securities" (as defined in the Securities and Futures Ordinance (Cap.571 of the Laws of Hong Kong)), the report is issued in Hong Kong by Citigroup Global Markets Asia Limited. Citigroup Global Markets Asia Limited is regulated by Hong Kong Securities and Futures Commission. If the report is prepared by a non-Hong Kong based analyst, please note that such analyst (and the legal entity that the analyst is employed by or accredited to) is not licensed/registered in Hong Kong and they do not hold themselves out as such. Please refer to the section "Research Analyst Affiliations / Non-US Research Analyst Disclosures" for the details of the employment entity of the analysts.

The Product is made available in **India** by Citigroup Global Markets India Private Limited (CGM), which is regulated by the Securities and Exchange Board of India (SEBI), as a Research Analyst (SEBI Registration No. INH000000438). CGM is also actively involved in the business of merchant banking (SEBI Registration No. INM000010718) and stock brokerage ((SEBI Registration No. INZ000263033) in India, and is registered with SEBI in this regard. Registration granted by SEBI and certification from National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors. CGM's registered office is at 1202, 12th Floor, First International Financial Centre (FIFC), G Block, Bandra Kurla Complex, Bandra East, Mumbai - 400098 & registered Tel: +91 22 61759999. CGM's Corporate Identity Number is U99999MH2000PTC126657, and its Compliance Officer [Vishal Bohra] contact details are: Tel:+91-022-61759994, Fax:+91-022-61759851, Email: cgmcompliance@citi.com. The Investor Charter in respect of Research Analysts and Complaints information can be found at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures. The grievance officer [Nikita Jadhav] contact details are Tel: +91-022-42775089, Email: EMEA.CR.Complaints@citi.com. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

The Product is made available in **Indonesia** through PT Citigroup Sekuritas Indonesia. Citibank Tower 10/F, Pacific Century Place, SCBD lot 10, Jl. Jend Sudirman Kav 52-53, Jakarta 12190, Indonesia. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Services Authority (OJK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of

Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations.

The Product is made available in **Japan** by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Otemachi Park Building, 1-1-1 Otemachi, Chiyoda-ku, Tokyo 100-8132 Japan. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help.

The product is made available in the **Kingdom of Saudi Arabia** in accordance with Saudi laws through Citigroup Saudi Arabia, which is regulated by the Capital Market Authority (CMA) under CMA license (17184-31). 2239 Al Urubah Rd – Al Olaya Dist. Unit No. 18, Riyadh 12214 – 9597, Kingdom Of Saudi Arabia.

The Product is made available in **Korea** by Citigroup Global Markets Korea Securities Ltd. (CGMK), which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). The address of CGMK is Citibank Center, 50 Saemunan-ro, Jongno-gu, Seoul 03184, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of

CGMK. <http://dis.kofia.or.kr/websquare/index.jsp?w2xPath=/wq/fundMgr/DISFundMgrAnalystList.xml&divisionId=MDISO3002002000000&serviceld=SDISO3002002000>. The Product is made available in Korea by Citibank Korea Inc., which is regulated by the Financial Services Commission and the Financial Supervisory Service. Address is Citibank Center, 50 Saemunan-ro, Jongno-gu, Seoul 03184, Korea. This research report is intended to be provided only to Professional Investors as defined in the Financial Investment Services and Capital Market Act and its Enforcement Decree in Korea.

The Product is made available in **Malaysia** by Citigroup Global Markets Malaysia Sdn Bhd (Registration No. 199801004692 (460819-D)) ("CGMM") to its clients and CGMM takes responsibility for its contents as regards CGMM's clients. CGMM is regulated by the Securities Commission Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product.

The Product is made available in **Mexico** by Citi México Casa de Bolsa, S.A. de C.V., Grupo Financiero Citi México which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comisión Nacional Bancaria y de Valores. Prolongación Reforma 1196, 24 floor, Colonia Santa Fe, Alcaldía Cuajimalpa de Morelos, C.P. 05348, Ciudad de México.

The Product is made available in **Poland** by Biuro Maklerskie Banku Handlowego (DMBH), separate department of Bank Handlowy w Warszawie S.A. a subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Biuro Maklerskie Banku Handlowego (DMBH), ul.Senatorska 16, 00-923 Warszawa.

The Product is made available in **Singapore** through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services and Exempt Financial Advisor license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This Product is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act 2001. For Citi Private Bank, the Product is made available in Singapore by Citi Private Bank through Citibank, N.A., Singapore Branch. Citibank N.A., Singapore Branch is a licensed bank in Singapore that is regulated by the Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. The Product is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act 2001. For Citibank Singapore Limited ("CSL"), the Product is distributed in Singapore by CSL to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of the Product. Please contact your Citigold//Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this document. The Product is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289).

Citigroup Global Markets (Pty) Ltd. is incorporated in the **Republic of South Africa** (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa.

The Product is made available in the **Republic of China (Taiwan)** through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14F, 15F and 16F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the license scope and the applicable laws and regulations in the Republic of China (Taiwan). CGMTS is regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China (Taiwan). No portion of the Product may be reproduced or quoted in the Republic of China (Taiwan) by the press or any third parties [without the written authorization of CGMTS]. Pursuant to the applicable laws and regulations in the Republic of China (Taiwan), the recipient of the Product shall not take advantage of such Product to involve in any matters in which the recipient may have conflicts of interest. If the Product covers securities which are not allowed to be offered or traded in the Republic of China (Taiwan), neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China (Taiwan). The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus.

The Product is made available in **Thailand** through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 399 Interchange 21 Building, 18th Floor, Sukhumvit Road, Klongtoey Nua, Wattana ,Bangkok 10110, Thailand.

The Product is made available in **Turkey** through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey.

In the **U.A.E**, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different Citi Research ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties.

The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA. This material may relate to investments or services of a person outside of the UK or to other matters which are not authorised by the PRA nor regulated by the FCA and the PRA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB.

The Product is made available in **United States** and **Canada** by Citigroup Global Markets Inc., which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013.

Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Europe AG ("CGME"), which is regulated by the European Central Bank and the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht-BaFin).

The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. The yield and average life of CMOs (collateralized mortgage obligations) referenced in this Product will fluctuate depending on the actual rate at which mortgage holders prepay the mortgages underlying the CMO and changes in current interest rates. Any government agency backing of the CMO applies only to the face value of the CMO and not to any premium paid. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product.

Citi Research product may source data from dataCentral. dataCentral is a Citi Research proprietary database, which includes the Firm's estimates, data from company reports and feeds from Thomson Reuters. The source for all referenced prices, unless otherwise stated, is DataCentral. Past performance is not a guarantee or reliable indicator of future results. Forecasts are not a guarantee or reliable indicator of future performance. The printed and printable version of the research report may not include all the information (e.g. certain financial summary information and comparable company data) that is linked to the online version available on the Firm's proprietary electronic distribution platforms.

Card Insights. Where this report references Card Insights data, Card Insights consists of selected data from a subset of Citi's proprietary credit card transactions. Such data has undergone rigorous security protocols to keep all customer information confidential and secure; the data is highly aggregated and anonymized so that all unique customer identifiable information is removed from the data prior to receipt by the report's author or distribution to external parties. This data should be considered in the context of other economic indicators and publicly available information. Further, the selected data represents only a subset of Citi's proprietary credit card transactions due to the selection methodology or other limitations and should not be considered as indicative or predictive of the past or future financial performance of Citi or its credit card business.

Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. Part of this product may contain Sustainalytics proprietary information that may not be reproduced, used, disseminated, modified nor published in any manner without the express written consent of Sustainalytics. Sustainalytics, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Any information attributed to Sustainalytics is provided solely for informational purposes and on its own should not be considered an offer to buy or sell a security. Neither Sustainalytics nor all its third-party suppliers provide investment advice (as defined in the applicable jurisdiction) or any other form of (financial) advice. The information is provided "as is" and, therefore Sustainalytics assumes no responsibility for errors or omissions. Sustainalytics cannot be held liable for damage arising from the use of this product or information contained herein in any manner whatsoever. Where data is attributed to Morningstar that data is © 2025 Morningstar, Inc. All Rights

Reserved. That information: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in any way form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

© 2025 Citigroup Global Markets Inc. Citi Research is a division of Citigroup Global Markets Inc. Citi and Citi and Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. The research data in this report are not intended to be used for the purpose of (a) determining the price of or amounts due in respect of (or to value) one or more financial products or instruments and/or (b) measuring or comparing the performance of, or defining the asset allocation of a financial product, a portfolio of financial instruments, or a collective investment undertaking, and any such use is strictly prohibited without the prior written consent of Citi Research. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST
